Status:
UNKNOWN
COVID-19 and Multiple Sclerosis Disease Modifying Therapies
Lead Sponsor:
Nottingham University Hospitals NHS Trust
Conditions:
Covid19
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The COVID-19 pandemic is a major concern for people on long-term treatments that modify the immune system function. People with multiple sclerosis (pwMS) form a large group who receive such treatments...
Eligibility Criteria
Inclusion
- Age 18 or above
- Diagnosed with MS
- Received treatment with a DMT
Exclusion
- Not fulfilling the inclusion criteria
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2022
Estimated Enrollment :
14240 Patients enrolled
Trial Details
Trial ID
NCT04863586
Start Date
April 1 2021
End Date
May 31 2022
Last Update
April 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nottingham University Hospitals NHS Trust
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH